Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), today announced the closing of its previously announced registered direct offering of 14,326,648 shares of its common stock and warrants to purchase up to 7,163,324 shares of its common stock, at a combined purchase price of $0.349 per share and associated warrant, for aggregate gross proceeds of approximately $5.0 million.
December 10, 2019
· 4 min read